Phase I Dose Ascending, Safety and Pharmacokinetics Study of APC148, a Novel Metallo-Beta-Lactamase Inhibitor in Healthy Volunteers

This Phase I randomized, placebo-controlled study demonstrates that APC148, a novel metallo-beta-lactamase inhibitor designed to be combined with meropenem and avibactam, is well tolerated and exhibits dose-proportional pharmacokinetics in healthy adults, supporting its potential as a promising therapeutic candidate for treating multidrug-resistant Gram-negative bacterial infections.

The Gist

Imagine the human body as a bustling city under siege by a very clever, heavily armored enemy: superbugs. These are bacteria that have learned to ignore our best weapons (antibiotics) by wearing special "armor" called enzymes.

For a long time, our main weapon, a drug called Meropenem, was like a powerful tank. But the superbugs developed a shield (an enzyme called a Metallo-β-lactamase) that could dissolve the tank's armor before it even hit the target.

Enter APC148, the hero of this story. Think of APC148 not as a weapon itself, but as a specialized locksmith. It doesn't kill the bacteria directly; instead, it finds the keyhole on the bacteria's shield and jams it shut. Once the shield is jammed, the Meropenem tank can roll right in and destroy the enemy.

The Story of the First Test (The "Phase I" Study)

Before we can use this new locksmith on sick people, we had to make sure it was safe to give to healthy people. This paper reports on that first-ever test in humans, conducted on 46 healthy volunteers in Sweden.

Here is what happened, broken down simply:

1. The Test Drive (The Study Design)
The researchers gave the volunteers a single dose of APC148 through an IV drip (like a slow, steady rain) over 3 hours. They started with a tiny amount (50 mg) and gradually increased the dose, like turning up the volume on a radio, until they reached a high dose (760 mg). They also had a control group who got a "sugar pill" (placebo) to compare results.

2. The Safety Check (Did it hurt?)
The big question was: Is this safe?

• The Verdict: Yes! The drug was very well tolerated.
• The "Scratches": Out of all the people who took the drug, only a few had minor side effects, like a mild headache, a little rash, or temporary muscle weakness. These were all mild, like a slight sunburn or a headache after too much coffee.
• The One Oddity: One woman at the highest dose had a tiny, temporary blip on her heart monitor (a slight change in heart rhythm). It went away on its own and wasn't dangerous, but it was noted just to be safe.
• No Crashes: Nobody got seriously sick, nobody had to leave the study, and nobody died.

3. The Journey Through the Body (Pharmacokinetics)
The researchers tracked how the drug moved through the volunteers' bodies, like watching a package travel through a postal system.

• Speed: The drug entered the bloodstream quickly and peaked right when the 3-hour drip finished.
• Duration: It stayed in the body for a while, with a "half-life" of about 2.6 hours. This means it stays around long enough to do its job but doesn't hang around forever.
• Exit Strategy: The body got rid of the drug mostly through the kidneys (peeing it out). This is great news because it suggests the drug will be very effective at treating infections in the urinary tract (like bladder infections), where it can concentrate naturally.

The Big Picture: Why This Matters

Think of the fight against superbugs as a game of chess. For years, the bacteria have been winning because they learned to break our pawns (antibiotics).

• The Problem: We have a great pawn (Meropenem), but the bacteria have a shield (Metallo-β-lactamase) that destroys it.
• The Solution: APC148 is the shield-breaker. When you combine Meropenem (the tank), Avibactam (a shield-breaker for other types of armor), and APC148 (the shield-breaker for this specific armor), you create a "super-team" that can defeat almost any bacteria.

The Conclusion

This paper is like a successful test drive of a new car engine. The engine (APC148) ran smoothly, didn't overheat, and didn't break down the car. It proved that this new "locksmith" is safe for humans and behaves exactly as the scientists hoped it would.

While this study was just on healthy people, the results are a huge green light. It means scientists can now move forward to test this powerful combination on patients who are actually sick with these dangerous, drug-resistant infections. It's a promising new tool in the fight to save lives from superbugs.

Technical Summary

1. Problem Statement

Antimicrobial resistance (AMR), particularly among Gram-negative bacteria, poses a critical global health threat. Carbapenem-resistant Enterobacterales (CRE), such as Klebsiella pneumoniae and Escherichia coli, are high-priority pathogens. These bacteria often produce two types of enzymes that degrade β-lactam antibiotics:

• Serine-β-lactamases (SBLs): Targeted by existing inhibitors (e.g., avibactam).
• Metallo-β-lactamases (MBLs): Including NDM, VIM, and IMP (Ambler class B enzymes). Currently, there are no approved therapies that combine β-lactam antibiotics with specific MBL inhibitors.

The lack of effective treatments for MBL-producing infections creates an urgent unmet medical need. APC148 was developed as a novel, selective zinc-inhibitor targeting MBLs to restore the efficacy of β-lactam antibiotics without intrinsic antibacterial activity.

2. Methodology

• Study Design: A first-in-human, randomized, double-blind, placebo-controlled, single-ascending-dose (SAD) trial.
• Setting: Conducted at a single clinical trial center in Uppsala, Sweden, between September 2024 and March 2025.
• Participants: 46 healthy adults (aged 18–60) with adequate renal function. The cohort included a higher proportion of males (67%).
• Intervention:
  • Six escalating dose cohorts received a single 3-hour intravenous (IV) infusion of APC148.
  • Doses: 50 mg, 150 mg, 300 mg, 450 mg, 650 mg, and 760 mg.
  • Randomization: Within each cohort, participants were randomized to APC148 or placebo (typically 6:2 ratio, except Cohort 1 which was 4:2).
  • Sentinel Dosing: The first two participants in each cohort were dosed sequentially (one drug, one placebo) to ensure safety before the rest of the cohort received the drug.
• Safety Monitoring: Adverse events (AEs), vital signs, 12-lead ECGs, clinical laboratory parameters (chemistry, hematology, coagulation, urinalysis), and physical examinations were monitored for 7 days post-dose.
• Pharmacokinetic (PK) Assessments:
  • Plasma: Samples collected pre-dose and up to 48 hours post-infusion.
  • Urine: Collected in intervals (0–6h, 6–12h, 12–24h) to measure renal excretion.
  • Analysis: Non-compartmental analysis (NCA) using Phoenix WinNonlin. Bioanalysis utilized UPLC-MS/MS.

3. Key Contributions

• First-in-Human Data: This study provides the inaugural safety and PK profile of APC148 in humans.
• Dose Escalation Strategy: Successfully navigated dose escalation up to 760 mg, adjusting the final step (from 650 mg to 760 mg) based on exposure limits observed in the previous cohort.
• Combination Potential: Validates the safety of APC148 as a component for combination therapy with meropenem (a carbapenem) and avibactam (an SBL inhibitor), aiming to cover both MBL and SBL producers simultaneously.

4. Results

Safety and Tolerability

• Overall: APC148 was well-tolerated at all dose levels.
• Adverse Events (AEs): All reported AEs were of mild intensity. No serious adverse events (SAEs), deaths, or discontinuations occurred.
• Specific Events: Five AEs were deemed related to APC148:
  • Erythema and rash (local tolerability).
  • Muscular weakness, headache.
  • ECG QT Prolongation: One female participant in the 760 mg cohort experienced a transient, asymptomatic QTcF prolongation (max 469 ms). This was noted as a single event with no clinical sequelae.
• Laboratory/Vitals: No clinically relevant changes were observed in safety labs, vital signs, or physical exams.

Pharmacokinetics (PK)

• Absorption/Distribution:
  • Cmax: Peak plasma concentrations occurred at the end of the 3-hour infusion.
  • Linearity: Exposure (Cmax and AUC) increased in a dose-proportional manner across the 50–760 mg range.
  • Half-life (T1/2): Mean terminal elimination half-life was 2.6 hours (range 2.3–3.0 h).
  • Clearance (CL): Low and dose-independent (mean ~10.5–12.0 L/h).
  • Volume of Distribution (Vss): Low to moderate (mean ~22–33 L).
• Elimination:
  • Renal Excretion: The primary route of elimination. The fraction of the dose excreted unchanged in urine (Fe%) ranged from 33% to 68%.
  • Renal Clearance: Ranged from 4.0 to 7.2 L/h.

5. Significance

• Clinical Viability: The study confirms that APC148 is safe and well-tolerated in humans at doses exceeding the estimated therapeutic range.
• Therapeutic Strategy: The PK profile (half-life of ~2.6 h) supports dosing regimens compatible with standard β-lactam antibiotics (like meropenem), facilitating the development of a triple-combination therapy (Meropenem + Avibactam + APC148).
• Targeting Resistance: By specifically inhibiting MBLs (NDM, VIM, IMP), APC148 addresses a critical gap in the antibiotic pipeline. When combined with avibactam (covering SBLs), this approach offers a potent solution for multidrug-resistant Gram-negative infections, including complicated urinary tract infections (suggested by high renal excretion).
• Future Development: The favorable safety and PK data support the progression of APC148 into further clinical trials for patients with serious infections caused by MBL-producing pathogens.